WuXi STA announced that its Active Pharmaceutical Ingredient manufacturing facility at Jinshan (Shanghai, China) has successfully passed its fourth inspection from the U.S. Food and Drug Administration – with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016. WuXi STA is the first CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the USA, China, EU, Canada, Switzerland, Australia, and New Zealand....